A Multicenter, Open-label Extension Study to Assess the Long-term Safety and Efficacy of an Oral Calcimimetic Agent AMG 073 (Cinacalcet) in Primary Hyperparathyroidism

Amgen

Status and phase

Completed

Phase 2

Conditions

Hyperparathyroidism, Primary

Treatments

Drug: cinacalcet

Study type

Interventional

Funder types

Industry

Identifiers

NCT00936988

20000159

Details and patient eligibility

About

This multicenter, open-label, single-arm, extension study was designed to evaluate long-term tolerability, safety, and efficacy of cinacalcet. Subjects were enrolled immediately after they completed the parent study, 990120. All subjects began treatment with 30 mg cinacalcet twice daily (BID), with dose adjustments made per protocol-specified guidelines. The study consisted of 2 consecutive phases that occurred in the following order: a dose-titration phase lasting 12 weeks and a maintenance phase lasting approximately 4½ years.

Enrollment

45 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Successfully completed the parent study 990120
Agreed to use highly effective (in the opinion of the principal investigator) contraceptive measures throughout the study
Were able to comprehend and were willing to give written informed consent for participation in the study

Exclusion criteria

Pregnant or breast-feeding
Had a psychiatric disorder that interfered with the understanding and giving of informed consent or compliance with protocol requirements
Had any other condition that reduced the chance of obtaining data (eg, known poor compliance)
Participating in another investigational study at the time of study entry
Had any unstable medical condition, defined as having been hospitalized within 28 days before day 1, or otherwise unstable in the judgment of the investigator